Suitability of a High-energy, Low-protein Formula (Renalive® LP)

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Sep 30, 2026 Re-verified, no change to tracked fields
2. Notable Sep 23, 2026 Primary and study completion dates: Apr 21, 2026 to Dec 31, 2027 Show 7 more changesShow less

   • Sponsor refiled this as recruiting (was completed)
   • Enrollment target: 74 to 80
   • Interventions: Renalive® LP, flavour Cappuccino (Dietary Supplement), Renalive® LP, flavour Vanilla (Dietary Supplement) to Renalive® LP, (Dietary Supplement)
   • Eligibility criteria shortened, about 263 words
   • Secondary endpoints shortened, about 133 words
   • Site details revised at 2 of 2 sites
   • Study title shortened, about 12 words
3. Minor Aug 27, 2026 Secondary endpoints revised (10)v6
4. Minor Aug 24, 2026 Eligibility criteria revised

   • Secondary endpoints revised (10)

   v5
5. Minor Jul 26, 2026 Re-verified, no change to tracked fieldsv4
6. Minor Apr 24, 2026 Trial completedv3 Show 4 more changesShow less

   • Enrollment target: estimated 80 to confirmed 74
   • Study sites: 3 to 2
   • Primary and study completion dates changed from estimate of Apr 30, 2026 to Apr 21, 2026
   • Eligibility criteria revised
7. Notable Mar 13, 2026 Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less

   • Study sites: 1 to 3
   • Primary completion date: Nov 15, 2025 to Apr 30, 2026
   • Start date changed from estimate of May 1, 2025 to Jun 4, 2025
   • Eligibility criteria revised
8. Minor Mar 18, 2025 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.